Access
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
Correspondence
Nature Medicine 15, 727 (1 July 2009) | doi:10.1038/nm0709-727
Reply to: |[ldquo]|Will integrin inhibitors have proangiogenic effects in the clinic?|[rdquo]|
&
Abstract
Reynolds et al. reply: Outcome in glioblastoma multiforme (GBM) is extremely poor, with median progression-free survival and overall survival of only 6.9 and 14.6 months, respectively.
To read this article in full you may need to log in, make a payment or gain access through a site license (see right).
